Search Results - marco+dal+molin

2 Results Sort By:
Identification of RNF43 Mutations in Pancreatic Cysts
Unmet Need·        One third of diagnoses for surgical resection of pancreatic cysts are incorrect, leading to unnecessary surgery, medical risk, and high costs (Hammel, 2002). The current standard of care for determining pancreatic cyst type is based solely on symptom progression and imaging criteria, and histopathological analysis is only available...
Published: 6/27/2024   |   Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Jian Wu, Anirban Maitra, Ralph Hruban, Marco Dal Molin
Keywords(s): Cancers, Cloning Reagents, Discovery/Research Tools, Disease Indication, Nucleotide, Pancreatic Cancer, Research Reagent, Translational Research Biomarker
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Research Tools > Nucleic Acids, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers
A p105-based NF-(kappa) B Super repressor
C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...
Published: 6/27/2024   |   Inventor(s): Li Lin
Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum